Compounds > bosentan anhydrous
Page last updated: 2024-08-26

bosentan anhydrous and Airflow Obstruction, Chronic

bosentan anhydrous has been researched along with Airflow Obstruction, Chronic in 18 studies

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (50.00)29.6817
2010's8 (44.44)24.3611
2020's1 (5.56)2.80

Authors

AuthorsStudies
Sakao, S1
Behr, J; Jungck, D; Knobloch, J; Koch, A; Konradi, J; Lin, Y; Stoelben, E; Strauch, J1
Lee, JS; Lee, SD; Oh, YM; Park, DA; Park, J; Song, JH1
Chabanne, C; Cordier, JF; Cottin, V; Delaval, P; Girard, A; Jouneau, S; Khouatra, C; Lannes, M; Traclet, J; Turquier, S1
Ando, K; Hoshika, Y; Ienaga, H; Kimura, T; Kuraishi, H; Morio, Y; Nagaoka, T; Takahashi, K; Tsutsumi, T1
Gerlach, K; Jungck, D; Knobloch, J; Knoop, H; Koch, A; Köhler-Bachmann, S; Körber, S; Kronsbein, J; Rheinländer, S; Walther, JW; Wehde, D; Yanik, S1
Hoeper, MM1
Ikeda, T; Ishikawa, S; Kobayashi, K; Takeyama, H; Tokuda, Y; Wakabayashi, K; Yano, S1
Argyropoulou, P; Boutou, AK; Pitsiou, G; Stanopoulos, I1
Jardim, C; Souza, R1
Canu, P; Cordier, JF; Cottin, V; Khouatra, C; Lazor, R1
Bracciale, P; Grazia D'Agostino, A; Valerio, G1
Chen, P; Chen, Y; Keishi, K; Masayuki, H; Peng, H; Yunden, D1
Cortijo, J; Gabarda, E; Guijarro, R; Juan, G; Martorell, M; Milara, J; Morcillo, EJ; Ortiz, JL1
Held, M; Jany, BH1
Maloney, JP1
Naeije, R1
Brutsche, M; Di Valentino, M; Linka, A; Meyer, A; Rasch, H; Stolz, D; Tamm, M1

Reviews

3 review(s) available for bosentan anhydrous and Airflow Obstruction, Chronic

ArticleYear
Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease.
    Journal of Korean medical science, 2013, Volume: 28, Issue:8

    Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Databases, Factual; Epoprostenol; Humans; Hypertension, Pulmonary; Hypoxia; Piperazines; Pulmonary Disease, Chronic Obstructive; Purines; Risk Factors; Sildenafil Citrate; Sulfonamides; Sulfones; Surveys and Questionnaires

2013
Advances in the treatment of secondary pulmonary hypertension.
    Current opinion in pulmonary medicine, 2003, Volume: 9, Issue:2

    Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Clinical Trials as Topic; Echocardiography; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Middle Aged; Piperazines; Pulmonary Disease, Chronic Obstructive; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents

2003
Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease.
    Proceedings of the American Thoracic Society, 2005, Volume: 2, Issue:1

    Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Piperazines; Pulmonary Disease, Chronic Obstructive; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents; Ventricular Dysfunction, Right

2005

Trials

2 trial(s) available for bosentan anhydrous and Airflow Obstruction, Chronic

ArticleYear
Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease.
    Therapeutic advances in respiratory disease, 2009, Volume: 3, Issue:1

    Topics: Aged; Antihypertensive Agents; Bosentan; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Plethysmography; Pulmonary Disease, Chronic Obstructive; Pulmonary Wedge Pressure; Sulfonamides; Treatment Outcome; Vascular Resistance

2009
A randomised, controlled trial of bosentan in severe COPD.
    The European respiratory journal, 2008, Volume: 32, Issue:3

    Topics: Aged; Bosentan; Double-Blind Method; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Hypoxia; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Sulfonamides; Vasodilator Agents

2008

Other Studies

13 other study(ies) available for bosentan anhydrous and Airflow Obstruction, Chronic

ArticleYear
Chronic lung disease-associated PH: PAH-approved drugs and established universal healthcare insurance in Japan.
    Respiratory investigation, 2020, Volume: 58, Issue:4

    Topics: Bosentan; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Insurance Coverage; Japan; Phenylpropionates; Prevalence; Prognosis; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Universal Health Insurance

2020
Inflammatory responses of airway smooth muscle cells and effects of endothelin receptor antagonism.
    American journal of respiratory cell and molecular biology, 2013, Volume: 49, Issue:1

    Topics: Airway Remodeling; Bosentan; Chemokines; Endothelin Receptor Antagonists; Gene Expression Regulation; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypertension, Pulmonary; Inflammation; Matrix Metalloproteinase 13; Myocytes, Smooth Muscle; Oligonucleotide Array Sequence Analysis; Phenylpropionates; Pulmonary Disease, Chronic Obstructive; Pyridazines; Receptors, Endothelin; RNA Stability; RNA, Messenger; Sulfonamides; Transcription, Genetic; Tumor Necrosis Factor-alpha

2013
Severe pulmonary hypertension associated with COPD: hemodynamic improvement with specific therapy.
    Respiration; international review of thoracic diseases, 2015, Volume: 90, Issue:3

    Topics: Aged; Bosentan; Cohort Studies; Comorbidity; Female; Follow-Up Studies; France; Hemodynamics; Hospitals, University; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Statistics, Nonparametric; Sulfonamides; Treatment Outcome; Vascular Resistance; Vasodilator Agents

2015
Potential Role of CT Metrics in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension.
    Lung, 2015, Volume: 193, Issue:6

    Topics: Aged; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Female; Forced Expiratory Volume; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Pulmonary Diffusing Capacity; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents; Vital Capacity

2015
Endothelin receptor-antagonists suppress lipopolysaccharide-induced cytokine release from alveolar macrophages of non-smokers, smokers and COPD subjects.
    European journal of pharmacology, 2015, Dec-05, Volume: 768

    Topics: Aged; Bosentan; Cytokines; Endothelin Receptor Antagonists; Female; Humans; Lipopolysaccharides; Macrophages, Alveolar; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Smoking; Sulfonamides

2015
Treating pulmonary hypertension in COPD: where do we start?
    The European respiratory journal, 2008, Volume: 32, Issue:3

    Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Sulfonamides; Vasodilator Agents

2008
[A case of severe pulmonary hypertension associated with COPD treated with epoprostenol].
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2008, Volume: 46, Issue:8

    Topics: Aged; Antihypertensive Agents; Bosentan; Epoprostenol; Humans; Hypertension, Pulmonary; Male; Pulmonary Disease, Chronic Obstructive; Sulfonamides

2008
Pulmonary hypertension therapy and COPD: still many questions to be answered.
    The European respiratory journal, 2009, Volume: 33, Issue:2

    Topics: Bosentan; Exercise; Humans; Hypertension, Pulmonary; Perfusion; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Treatment Outcome; Ventricular Dysfunction, Left

2009
Pulmonary hypertension therapy and COPD: still many questions to be answered.
    The European respiratory journal, 2009, Volume: 33, Issue:2

    Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Lung; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Research Design; Sulfonamides; Treatment Outcome

2009
Pulmonary hypertension therapy and COPD: still many questions to be answered.
    The European respiratory journal, 2009, Volume: 33, Issue:2

    Topics: Antihypertensive Agents; Bosentan; Humans; Hypertension, Pulmonary; Lung; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Research Design; Sulfonamides; Treatment Outcome

2009
[The mechanism and pulmonary-protective effects of endothelin-1 receptor antagonist in chronic obstructive pulmonary diseases rat model].
    Zhonghua nei ke za zhi, 2010, Volume: 49, Issue:5

    Topics: Animals; Antihypertensive Agents; Apoptosis; Bosentan; Caspase 3; Endothelin A Receptor Antagonists; Interleukin-1beta; Lung; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Peptides, Cyclic; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Rats; Rats, Sprague-Dawley; Sulfonamides; Tumor Necrosis Factor-alpha

2010
Bosentan inhibits cigarette smoke-induced endothelin receptor expression in pulmonary arteries.
    The European respiratory journal, 2012, Volume: 39, Issue:4

    Topics: Aged; Antihypertensive Agents; Autocrine Communication; Bosentan; Cell Division; Cells, Cultured; Humans; Hypertension, Pulmonary; MAP Kinase Signaling System; Middle Aged; Muscle, Smooth, Vascular; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Reactive Oxygen Species; Receptor, Endothelin A; Receptor, Endothelin B; rhoA GTP-Binding Protein; Smoking; Sulfonamides; Up-Regulation; Vasoconstriction

2012
Pulmonary hypertension in COPD.
    Respiratory care, 2013, Volume: 58, Issue:8

    Topics: Aged; Antihypertensive Agents; Atrial Fibrillation; Bosentan; Comorbidity; Coronary Artery Disease; Exercise Test; Female; Humans; Hypertension, Pulmonary; Male; Pulmonary Diffusing Capacity; Pulmonary Disease, Chronic Obstructive; Sulfonamides; Treatment Outcome; Vasoconstriction; Vasoconstrictor Agents

2013